What is VaxNewMo?
VaxNewMo is dedicated to developing more affordable pneumococcal conjugate vaccines that provide broader protection against more strains of bacteria that cause pneumococcal pneumonia. To do this, we utilize our patented bioconjugation technology, which bypasses the dependency on the synthetic chemistry techniques previously required to manufacture conjugate vaccines. In essence, we have engineered the lab safe bacterium, E. coli, to manufacture pneumococcal conjugate vaccines faster, more reliable, and less expensive than traditional pharmaceutical companies can.
Be a Part of the Movement
We champion extraordinary entrepreneurs to create positive change – for St. Louis and for the world. Join us by applying to our Global Startup Competition, becoming a financial supporter, volunteering your time or amplifying our message.